We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-9 of 9

Productivity Commission makes pharma-specific patent reform recommendations
  • Piper Alderman
  • Australia
  • May 11 2016

The Productivity Commission (Commission), as independent advisory agency of the Commonwealth Government, has released a draft report (Draft Report)


High Court dismisses AstraZeneca Crestor appeal
  • Piper Alderman
  • Australia
  • September 2 2015

This morning the High Court of Australia unanimously dismissed AstraZeneca's appeal from the Full Federal Court's August 2014 decision in which


ACCC v Pfizer judgment summary and ramifications
  • Piper Alderman
  • Australia
  • February 27 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian


Innovative arguments by innovator
  • Piper Alderman
  • Australia
  • February 18 2015

The Federal Court has ordered Pharmacor to provide preliminary discovery to GlaxoSmithKline Australia of evidence regarding Osteomol 665, a competitor


The Raising the Bar Act improving Australia’s intellectual property regime
  • Piper Alderman
  • Australia
  • September 13 2012

The Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Act) was passed by the House of Representatives on 20 March 2012 and received Royal Assent on 15 April 2012.


The patentability of biological material summary of public submissions to senate inquiry
  • Piper Alderman
  • Australia
  • June 7 2011

The patentability of biological material is a highly contentious issue within the scientific community and a Bill currently before a Senate committee has generated further debate.


The public debate about the patentability of biological material: is it much ado about nothing?
  • Piper Alderman
  • Australia
  • February 11 2011

For more than 20 years, the patentability of genes and genetic material has been controversial.



Tim Clark
  • Piper Alderman